Another hope for multiple sclerosis patients. Improved Interferon-beta patent recently granted byAugust 06, 2003Blurred vision, weak limbs, tingling sensations, unsteadiness and fa-tigue are the symptoms of one of the most common diseases of the central nervous system, the multiple sclerosis (MS). It is estimated that MS currently affects over 2,500,000 people worldwide. There is new hope for MS patients: The protein Interferon-beta, which is produced in bacterial or mammalian cells by genetic engineering, is being used successfully in the treatment of multiple sclerosis. However, the very high hydrophobicity and thus poor solubility of Interferon-beta, proves to be problematic for the production and clinical efficacy of recombinant human Interferon-beta. In order to solve this problem, scientists from the German Fraunhofer Institute for Interfacial Engineering and Biotechnology (Fraunhofer-Institut für Grenzfl'¤chen- und Bioverfahrenstechnik IGB) designed variants of recombinant human Interferon-beta whose solubility is improved. They replaced the hydrophobic portions of the molecule by soluble ones. This technique is known as hydrophobicity engineering. »Our goal was to reduce clustering between the molecules in order to increase the protein yield and thus pharmacological effectiveness«, says Professor Bernd Otto. »Moreover, the improved hydrophilicity of these modified proteins simplifies their manufacture, transportation, storage and application as a medicinal drug«, Otto specifies further advantages of the improved Interferon-beta. The researchers' success becomes outstanding on a global level, as in June 2003 the US Patent and Trademark Office granted a patent on recombinant human beta-interferon with enhanced solubility (United States Patent 6,572,853) caused by the substitution of nine amino acids on its surface. Additionally, the European Patent Office just announced its willingness to grant a patent for the whole of the European states, the German patent has already been granted. The patented variant has been expressed and purified from bacterial (E. coli) as well as mammalian (CHO) cells. In both cases, the variant shows a highly increased pharmacokinetic stability and bioavailability when investigated in animal experiments. For clinical studies, therefore, there is the hope of fewer side-effects and enhanced effectiveness in the therapy of MS. Furthermore, the soluble Interferon-beta will also be suitable for the therapy of other viral and oncological indications. Negotiations with pharmaceutical companies will be intensified.
Fraunhofer Institut - Grenzflächen- und Bioverfahrenstechnik (IGB) | |||||||||||||||||||||
|
Related Multiple Sclerosis Current Events and Multiple Sclerosis News Articles Melatonin may save eyesight in inflammatory disease Current research suggests that melatonin therapy may help treat uveitis, a common inflammatory eye disease. The related report by Sande et al., "Therapeutic Effect of Melatonin in Experimental Uveitis," appears in the December issue of The American Journal of Pathology. Researcher tricks immune system in diabetic mice The body's immune system hates strangers. When its security patrol spots a foreign cell, it annihilates it. In the war against diseases, nerve cells need their armor In a new study, researchers at the Montreal Neurological Institute (MNI), McGill University, and the Université de Montréal have discovered an essential mechanism for the maintenance of the normal structure of myelin, the protective covering that insulates and supports nerve cells (neurons). Intraspinal implant of mesenchymal stem cells may not heal the demyelinated spinal cord Multiple sclerosis is a disease caused by the loss of the myelinated sheath surrounding the nerve fibers of the spinal cord. Multiple sclerosis research charges ahead with new mouse model of disease A new study highlights the role of a charge-switching enzyme in nervous system deficits characteristic of multiple sclerosis and other related neurological illness. Lung airway cells activate vitamin D and increase immune response Vitamin D is essential to good health but needs to be activated to function properly in the human body. Until recently, this activation was thought to happen primarily in the kidneys, but a new University of Iowa study finds that the activation step can also occur in lung airway cells. Type-1 diabetes not so much bad genes as good genes behaving badly, Stanford research shows Investigators combing the genome in the hope of finding genetic variants responsible for triggering early-onset diabetes may be looking in the wrong place, new research at the Stanford University School of Medicine suggests. Phase IIb data show that BG-12 significantly reduced brain lesions in multiple sclerosis Biogen Idec (NASDAQ: BIIB) today announced the publication of Phase IIb data showing that a 240 mg three-times-daily dose of the company's novel oral compound, BG-12 (BG00012, dimethyl fumarate), reduced the number of new gadolinium enhancing (Gd+) lesions by 69 percent in patients with relapsing-remitting multiple sclerosis (MS) when compared to treatment with placebo (p<0.0001). New hope for multiple sclerosis sufferers A drug which was developed in Cambridge and initially designed to treat a form of leukaemia has also proven effective against combating the debilitating neurological disease multiple sclerosis (MS). Genetic analysis predicts whether liver cancer likely to recur Researchers are poised to unlock the genetic secrets stored in hundreds of thousands of cancer biopsy samples locked in long-term storage and previously thought to be useless for modern genetic research. More Multiple Sclerosis Current Events and Multiple Sclerosis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||